The challenges surrounding the accessibility of Paxlovid, a potential game-changer in the fight against COVID-19, have raised concerns about the distribution and utilization of this antiviral drug. Despite its demonstrated efficacy in preventing hospitalization and reducing the risk of severe illness and death, several factors have contributed to the limited availability and uptake of Paxlovid among the patients who could benefit the most